Form 4: Ultragenyx CFO Sells Shares in Pre-Planned Transaction

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, sold 3,150 shares of common stock for $22.84 per share in a pre-planned transaction.

Summary

• Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., disposed of 3,150 shares of common stock.
• The transaction occurred on January 2, 2026, at a price of $22.84 per share.
• Following the sale, Horn beneficially owns 91,996 shares of common stock directly.
• The sale was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction.
• The remaining beneficial ownership includes shares underlying Restricted Stock Units (RSUs) subject to vesting conditions.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of an insider stock sale executed under a pre-planned 10b5-1 agreement, which typically has a neutral impact on sentiment as it does not reflect new discretionary trading decisions based on recent company performance or outlook.

Future Outlook

NA

Industry Context

This is a routine insider transaction disclosure for a biotechnology company. Such sales are common for executives managing their personal portfolios, especially when executed under a 10b5-1 plan, which helps avoid accusations of trading on inside information.

Stakeholder Impact

• Shareholders may note the Chief Financial Officer's sale of shares, though the 10b5-1 plan suggests it is not based on new material non-public information.

Key Dates

Recommendation

The filing details a routine, pre-planned insider sale by the CFO under a 10b5-1 plan. Such transactions are generally neutral and do not provide new information to warrant a change in investment recommendation. The company's fundamentals and broader market conditions would be the primary drivers for any buy or sell decision.

Keywords

Ultragenyx Pharmaceutical, RARE, Howard Horn, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Beneficial Ownership, Common Stock